DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

FILE COPY

November 2, 2006

Alessandra C. Ravetti &
Emily Marden
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

Dear Ms. Ravetti and Marden:

Your petition requesting the Food and Drug Administration to revoke the approval of the Allergan Inc. supplemental NDA #21-257/S-013 for Lumigan (bimatoprost ophthalmic solution 0.03%) and deny Alcon Inc. supplemental NDA for Travatan (travoprost ophthalmic solution 0.004%), was received by this office on 11/02/2006. It was assigned docket number 2006P-0450/CP1 and it was filed on 11/02/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Jennie C Butler

Jennie Butler, Director
Division of Dockets Management
Office of Management Programs
Office of Management

2006P-0450

ACK 1